Quantitative structure--plasma protein binding relationships of acidic drugs.

One of the most important factors, affecting significantly the overall pharmacokinetic and pharmacodynamic profile of a drug, is its binding to plasma protein (PPB). In the present study, we focus on a set of 132 diverse acidic drugs binding to plasma proteins to different extent and develop quantitative structure-plasma protein binding relationships (QSPPBR) to predict their unbound fraction in plasma (f(u)) using 178 molecular descriptors. QSPPBR models were derived after variable selection by genetic algorithm followed by stepwise regression and tested by cross- and external validation. The final model has r(2) value of 0.771, q(2) value of 0.737, and four outliers. It predicts 57% of the f(u) values with less than twofold error. According to the molecular descriptors selected as the most predictive for PPB, the lipophilicity of the drugs, the presence of aromatic rings, cyano groups, and H-bond donor-acceptor pairs increase the PPB, whereas the presence of tertiary carbon atoms, four-member rings, and iodine atoms decrease PPB. These descriptors were summarized into a short seven-item checklist of criteria responsible for PPB. The checklist could be used as a guide for evaluation of PPB of acidic drug candidates, similarly to the Lipinski's rule of five used for evaluation of oral permeability of drugs.

[1]  George W. A. Milne,et al.  An Integrated in Silico Analysis of Drug-Binding to Human Serum Albumin , 2006, J. Chem. Inf. Model..

[2]  R. Mehvar.  Role of Protein Binding in Pharmacokinetics , 2005 .

[3]  D. C. Carter,et al.  Atomic structure and chemistry of human serum albumin , 1993, Nature.

[4]  Z H Israili,et al.  HUMAN ALPHA-1-GLYCOPROTEIN AND ITS INTERACTIONS WITH DRUGS†,‡ , 2001, Drug metabolism reviews.

[5]  Ruisheng Zhang,et al.  QSAR Models for the Prediction of Binding Affinities to Human Serum Albumin Using the Heuristic Method and a Support Vector Machine. , 2004 .

[6]  Yi Li,et al.  Constructing plasma protein binding model based on a combination of cluster analysis and 4D-fingerprint molecular similarity analyses. , 2006, Bioorganic & medicinal chemistry.

[7]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[8]  T. Imai,et al.  Drug Binding to α1-Acid Glycoprotein Studied by Circular Dichroism , 2004, Pharmaceutical Research.

[9]  J. Freidman,et al.  Multivariate adaptive regression splines , 1991 .

[10]  H. van de Waterbeemd,et al.  ADMET in silico modelling: towards prediction paradise? , 2003, Nature reviews. Drug discovery.

[11]  Omar Deeb,et al.  Correlation ranking and stepwise regression procedures in principal components artificial neural networks modeling with application to predict toxic activity and human serum albumin binding affinity , 2010 .

[12]  T. Kennedy.  Managing the drug discovery/development interface , 1997 .

[13]  R. Boggia,et al.  Genetic algorithms as a strategy for feature selection , 1992 .

[14]  Akash Khandelwal,et al.  In silico ADME modelling 2: computational models to predict human serum albumin binding affinity using ant colony systems. , 2006, Bioorganic & medicinal chemistry.

[15]  Ruisheng Zhang,et al.  QSAR Models for the Prediction of Binding Affinities to Human Serum Albumin Using the Heuristic Method and a Support Vector Machine , 2004, J. Chem. Inf. Model..

[16]  G. Sudlow,et al.  Further characterization of specific drug binding sites on human serum albumin. , 1976, Molecular pharmacology.

[17]  Junmei Wang,et al.  Chapter 5 Recent Advances on in silico ADME Modeling , 2009 .

[18]  J. Lavandera,et al.  Cheminformatic models to predict binding affinities to human serum albumin. , 2001, Journal of medicinal chemistry.

[19]  P. Hajduk,et al.  Rational design of diflunisal analogues with reduced affinity for human serum albumin. , 2001, Journal of the American Chemical Society.

[20]  Bhupinder Singh,et al.  Quantitative correlation between theoretical molecular descriptors and drug‐HSA binding affinities for various cox‐2 inhibitors , 2008, Chemical biology & drug design.

[21]  S. Curry,et al.  Crystal Structure Analysis of Warfarin Binding to Human Serum Albumin , 2001, The Journal of Biological Chemistry.

[22]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[23]  Kazuto Yamazaki,et al.  Computational prediction of the plasma protein-binding percent of diverse pharmaceutical compounds. , 2004, Journal of pharmaceutical sciences.

[24]  Lemont B. Kier,et al.  Modeling Drug Albumin Binding Affinity with E-State Topological Structure Representation , 2003, J. Chem. Inf. Comput. Sci..

[25]  S. Chanock,et al.  Human Pharmacogenomic Variations and Their Implications for Antifungal Efficacy , 2006, Clinical Microbiology Reviews.

[26]  Yvonne C. Martin,et al.  Ligand binding to domain-3 of human serum albumin: a chemometric analysis , 2003, J. Comput. Aided Mol. Des..

[27]  Alexander Tropsha,et al.  QSAR modeling of human serum protein binding with several modeling techniques utilizing structure-information representation. , 2006, Journal of medicinal chemistry.

[28]  Franco Lombardo,et al.  Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 670 Drug Compounds , 2008, Drug Metabolism and Disposition.

[29]  J. Leggett,et al.  Influence of Assay Methodology on the Measurement of Free Serum Ceftriaxone Concentrations , 1998, Antimicrobial Agents and Chemotherapy.

[30]  G. Sudlow,et al.  The characterization of two specific drug binding sites on human serum albumin. , 1975, Molecular pharmacology.

[31]  Manfred Kansy,et al.  Predicting plasma protein binding of drugs: a new approach. , 2002, Biochemical pharmacology.

[32]  Yi Li,et al.  Prediction of plasma protein binding of drugs using Kier–Hall valence connectivity indices and 4D-fingerprint molecular similarity analyses , 2005, J. Comput. Aided Mol. Des..

[33]  Edward H. Kerns,et al.  Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization , 2008 .

[34]  M. Medina-Hernández,et al.  Characterization of basic drug–human serum protein interactions by capillary electrophoresis , 2006, Electrophoresis.

[35]  Lemont B. Kier,et al.  QSAR modeling of β-lactam binding to human serum proteins , 2003, J. Comput. Aided Mol. Des..

[36]  Stephan Schmidt,et al.  Significance of protein binding in pharmacokinetics and pharmacodynamics. , 2010, Journal of pharmaceutical sciences.

[37]  Dion R. Brocks,et al.  Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery , 2008, Nature Reviews Drug Discovery.

[38]  In silico ADME modeling: QSPR models for the binding of β- lactams to human serum proteins using genetic algorithms , 2004 .

[39]  Lijuan Chen,et al.  Results of molecular docking as descriptors to predict human serum albumin binding affinity. , 2012, Journal of molecular graphics & modelling.

[40]  Ferenc Zsila,et al.  Evaluation of drug-human serum albumin binding interactions with support vector machine aided online automated docking , 2011, Bioinform..

[41]  S. Curry,et al.  Structural basis of the drug-binding specificity of human serum albumin. , 2005, Journal of molecular biology.

[42]  Bahram Hemmateenejad,et al.  ANN‐QSAR Model of Drug‐binding to Human Serum Albumin , 2007, Chemical biology & drug design.

[43]  Kamaldeep K. Chohan,et al.  Advancements in Predictive In Silico Models for ADME , 2008 .

[44]  L. H. Hall and L.B. Kier.  Molecular Connectivity Chi Indices for Database Analysis and Structure-Property Modeling , 2000 .